Literature DB >> 23323145

The changing landscape in the treatment of metastatic castration-resistant prostate cancer.

Joelle El-Amm1, Jeanny B Aragon-Ching.   

Abstract

The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking.

Entities:  

Keywords:  Androgen deprivation therapy; chemotherapy; metastatic castration-resistant prostate cancer; vaccine therapy

Year:  2013        PMID： 23323145      PMCID： PMC3539272          DOI： 10.1177/1758834012458137

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  60 in total

Review 1.  Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.

Authors:  E David Crawford; Thomas W Flaig
Journal:  Oncology (Williston Park)       Date:  2012-01       Impact factor: 2.990

2.  Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

Authors:  Venkatesh D Handratta; Tadas S Vasaitis; Vincent C O Njar; Lalji K Gediya; Ritesh Kataria; Pankaj Chopra; Donnell Newman; Rena Farquhar; Zhiyong Guo; Yun Qiu; Angela M H Brodie
Journal:  J Med Chem       Date:  2005-04-21       Impact factor: 7.446

Review 3.  From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.

Authors:  Ravi A Madan; Jeanny B Aragon-Ching; James L Gulley; William L Dahut
Journal:  Expert Rev Vaccines       Date:  2011-06       Impact factor: 5.217

4.  Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

Authors:  Yang-Min Ning; James L Gulley; Philip M Arlen; Sukyung Woo; Seth M Steinberg; John J Wright; Howard L Parnes; Jane B Trepel; Min-Jung Lee; Yeong Sang Kim; Haihao Sun; Ravi A Madan; Lea Latham; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

5.  Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

Authors:  Jeanny B Aragon-Ching; Yang-Min Ning; Clara C Chen; Lea Latham; Jean-Pierre Guadagnini; James L Gulley; Philip M Arlen; John J Wright; Howard Parnes; William D Figg; William L Dahut
Journal:  Cancer Invest       Date:  2009-02       Impact factor: 2.176

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.

Authors:  Oliver Sartor; Robert H Reid; Peter J Hoskin; Donald P Quick; Peter J Ell; Robert E Coleman; Jon A Kotler; Leonard M Freeman; Pierre Olivier
Journal:  Urology       Date:  2004-05       Impact factor: 2.649

8.  Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Authors:  Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

Review 9.  Taxane refractory prostate cancer.

Authors:  Paul Mathew; Robert Dipaola
Journal:  J Urol       Date:  2007-07-20       Impact factor: 7.450

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531
View more
  22 in total

1.  Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.

Authors:  Archana Mukhopadhyay; Kayann Tabanor; Rathnam Chaguturu; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2013-08-05       Impact factor: 4.742

2.  Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.

Authors:  Arun K Nalla; Theodore F Williams; Casey P Collins; Dustin T Rae; Grant D Trobridge
Journal:  Mol Carcinog       Date:  2015-10-29       Impact factor: 4.784

3.  Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.

Authors:  Melissa A Babcook; Sanjeev Shukla; Pingfu Fu; Edwin J Vazquez; Michelle A Puchowicz; Joseph P Molter; Christine Z Oak; Gregory T MacLennan; Chris A Flask; Daniel J Lindner; Yvonne Parker; Firouz Daneshgari; Sanjay Gupta
Journal:  Mol Cancer Ther       Date:  2014-08-13       Impact factor: 6.261

Review 4.  Prognostic Utility of PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2015-01-22

Review 5.  Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.

Authors:  Matt Shirley; Paul L McCormack
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

6.  Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.

Authors:  David M Albala
Journal:  Rev Urol       Date:  2017

7.  Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells.

Authors:  Serge Ginzburg; Konstantin V Golovine; Petr B Makhov; Robert G Uzzo; Alexander Kutikov; Vladimir M Kolenko
Journal:  Prostate       Date:  2013-10-22       Impact factor: 4.104

8.  CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.

Authors:  Jemima Escamilla; Shiruyeh Schokrpur; Connie Liu; Saul J Priceman; Diana Moughon; Ziyue Jiang; Frederic Pouliot; Clara Magyar; James L Sung; Jingying Xu; Gang Deng; Brian L West; Gideon Bollag; Yves Fradet; Louis Lacombe; Michael E Jung; Jiaoti Huang; Lily Wu
Journal:  Cancer Res       Date:  2015-03-03       Impact factor: 12.701

9.  Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.

Authors:  Raji Shameem; Muhammad Saad Hamid; Kevin Y Xu; Shenhong Wu
Journal:  World J Clin Oncol       Date:  2015-08-10

Review 10.  Genomic Rearrangements of PTEN in Prostate Cancer.

Authors:  Sopheap Phin; Mathew W Moore; Philip D Cotter
Journal:  Front Oncol       Date:  2013-09-17       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.